We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).
Fusco V., Campisi G., & Bedogni A. (2020). Adjuvant denosumab in early breast-cancer. THE LANCET ONCOLOGY, 21(3), e124 [10.1016/S1470-2045(20)30066-8].
Data di pubblicazione: | 2020 | |
Titolo: | Adjuvant denosumab in early breast-cancer | |
Autori: | ||
Citazione: | Fusco V., Campisi G., & Bedogni A. (2020). Adjuvant denosumab in early breast-cancer. THE LANCET ONCOLOGY, 21(3), e124 [10.1016/S1470-2045(20)30066-8]. | |
Rivista: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/S1470-2045(20)30066-8 | |
Abstract: | We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ). | |
Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
PIIS1470204520300668.pdf | Versione Editoriale | Administrator Richiedi una copia |